BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/7/2023 7:47:34 AM | Browse: 133 | Download: 180
 |
Received |
|
2022-12-27 20:04 |
|
Peer-Review Started |
|
2022-12-27 20:05 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-01-11 01:44 |
|
Revised |
|
2023-01-19 01:05 |
|
Second Decision |
|
2023-04-11 03:03 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2023-04-11 18:05 |
|
Articles in Press |
|
2023-04-11 18:05 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-04-23 02:18 |
|
Publish the Manuscript Online |
|
2023-05-07 07:47 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Review |
| Article Title |
Current and novel approaches in the pharmacological treatment of hepatocellular carcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Fernanda Villarruel-Melquiades, María Eugenia Mendoza-Garrido, Claudia M García-Cuellar, Yesennia Sánchez-Pérez, Julio Isael Pérez-Carreón and Javier Camacho |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| CONACyT Fellowship (FV-M) |
787907 |
|
| Corresponding Author |
Javier Camacho, BSc, MSc, PhD, Research Scientist, Departamento de Farmacología, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), Avenida Instituto Politécnico Nacional 2508, Mexico City 07360, Mexico. fcamacho@cinvestav.mx |
| Key Words |
Liver cancer; Systemic therapy; Immunotherapy; Drug repurposing; Drug combinations; Hepatocellular carcinoma |
| Core Tip |
Hepatocellular carcinoma (HCC) is one of the most lethal malignant tumours worldwide. Unfortunately, most HCC cases are diagnosed at an advanced stage, and "curative" options are not suggested for these patients. The best option is to start with drug therapy, with sorafenib and lenvatinib as the first-choice drugs. However, most patients do not respond to these treatments; therefore, new therapeutic strategies are urgently needed. Here, we review current potential and novel pharmacological approaches, including immunotherapy, drug combination, and drug repositioning, that should help to improve the prognosis of HCC patients. |
| Publish Date |
2023-05-07 07:47 |
| Citation |
Villarruel-Melquiades F, Mendoza-Garrido ME, García-Cuellar CM, Sánchez-Pérez Y, Pérez-Carreón JI, Camacho J. Current and novel approaches in the pharmacological treatment of hepatocellular carcinoma. World J Gastroenterol 2023; 29(17): 2571-2599 |
| URL |
https://www.wjgnet.com/1007-9327/full/v29/i17/2571.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v29.i17.2571 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
